Tempus AI news and events in 2026
Tempus provides precision medicine services by integrating clinical and molecular data through a machine learning platform. The organization develops diagnostic tools and algorithmic models for use in oncology, cardiology, radiology, and depression.
Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn
Get Tempus AI's live signals in Claude or ChatGPT, or by API
What changed at Tempus AI this week? Use Autobound signals for tempus.com.- Dated updates
- 98
- Last event
- Nov 2, 2026
- Open rolesSnapshot Nov 3, 2026
- 87
- Latest SEC filing
- Nov 2, 2026
Source: Autobound Signal API · 98 signals tracked for Tempus AI · updated
Overview
Tempus AI by topic
110-K filing
87open roles
1deal
1executive move
70+signals
27 in the last 90 days
- Glassdoor15+
- LinkedIn15+
- Website changes15+
- YouTube12
- and 3 more sources
Latest events
Latest Tempus AI events
Showing 10 of 19 events. The Signal API returns all of them.
Get them with one API call- New customerPathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical researchTempus AI signed a $55 million agreement with Pathos AI to provide five-year access to a neurological disease patient database.
- News
- In developmentTempus AI (TEM) Unveils Whole Genome Platform With Plans For 1 Million GenomesAnnounced a new whole-genome sequencing initiative and platform linked to clinical data for AI research, with general availability planned for mid-2027.
- LaunchTempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGsWith U.S. Food and Drug Administration
- RevenueTempus AI posts first GAAP profit, boosts 2026 revenue forecast to $1.6B with FDA approval aiding growthTempus AI raised its 2026 revenue forecast to between $1.595 billion and $1.605 billion.
- AwardTempus AI's FDA Win Could Unlock Major Reimbursement Growth AheadWith Food and Drug Administration
- In developmentTempus AI's FDA Win Could Unlock Major Reimbursement Growth AheadWith U.S. Food and Drug Administration
- EarningsIs Tempus AI Worth Buying as Growth Improves but Valuation Stays High?Tempus AI reported a second-quarter GAAP net income of $5.6 million.
- PartnershipCellCarta Adds Tempus to CDx Commercialization Lab NetworkTempus AI has joined CellCarta's CDx Commercialization Lab Network as its second commercial laboratory partner to support oncology-focused access.
- Acquisition
Showing 10 of 19 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Tempus AI with the Signal API
One POST /v1/companies/enrich call with tempus.com returns every signal type for Tempus AI, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"tempus.com","limit":20}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Company pages
Companies related to Tempus AI
Tempus AI questions
What is the latest news on Tempus AI?
What is going on with Tempus AI?
Has Tempus AI announced any acquisitions?
What else does Autobound track for Tempus AI?
Is Tempus AI hiring right now?
Page updated , the date of the newest row on this page.
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .